Skip to main content
Premium Trial:

Request an Annual Quote

EMD Millipore Acquires Rights to Singulex's Life Science Research Business

NEW YORK (GenomeWeb) – Singulex announced today that it has signed an agreement giving EMD Millipore, a unit of Germany's Merck KGaA, the rights to control and manage its life science research business, which includes the company's single-molecule counting (SMC) technology.

The SMC technology enables the detection of single molecules such as proteins and metabolites in complex biological samples. It is the basis for Singulex's research-use-only Erenna instrument, which can detect single molecules down to the femtogram level.

Under the new deal, EMD Millipore will have the exclusive rights to further develop and commercialize the SMC technology for research applications. In exchange, Singulex will receive an undisclosed upfront payment, royalties on product sales, and additional payments based on the achievement of certain commercial milestones.

Singulex retains the rights to the technology for use in its clinical lab testing and in vitro diagnostics businesses.

Additional terms of the arrangement were not disclosed.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.